JPRN-jRCT2080221904未知1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study
- •- Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist
- •- Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks.
- •- Patients who have at least one lesion that can be accurately assessed
排除标准
- •- Patients who have recently received or are receiving prohibited medications or treatments
- •- Patients who have any unresolved side effects of previous treatments
- •- Patients who have spinal cord compression or brain metastases
- •- Patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis B, hepatitis C and human immunodeficiency virus [HIV] infection)
- •- Patients with significant abnormal ECG findings
研究者
相似试验
未知
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant MesotheliomaJPRN-jRCT2080222502AstraZeneca
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 uUnder Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.Advanced Solid Malignancy, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial CancerJPRN-jRCT2080222792AstraZeneca KK25
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid MalignanciesJPRN-jRCT2080222811AstraZeneca
已完成
1 期
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid Malignancy, Advanced Solid TumorJPRN-jRCT2080221764AstraZeneca KK41
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)Patients With Non-Small Cell Lung Cancer(NSCLC)JPRN-jRCT2080222721AstraZeneca KK9